Trials / Completed
CompletedNCT00811642
Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)
A Multicenter, Open Label Study to Evaluate Safety and Efficacy of Posaconazole Oral Suspension in Treatment of Invasive Fungal Infection
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this multicenter, open label study, is to evaluate the safety and efficacy of a 12-week treatment with Posaconazole Oral Suspension in participants with IFI
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Posaconazole | 400mg BID oral suspension for 12 weeks |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2010-03-01
- Completion
- 2010-03-01
- First posted
- 2008-12-19
- Last updated
- 2017-04-07
- Results posted
- 2011-04-29
Source: ClinicalTrials.gov record NCT00811642. Inclusion in this directory is not an endorsement.